Status:
ENROLLING_BY_INVITATION
Penn Medicine Biobank Return of Results Program
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Fox Chase Cancer Center
Columbia University
Conditions:
Genetic Disease
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants. The main questions the study aims to...
Detailed Description
The scientific aims of the study are: Aim 1 (Effectiveness of eHealth return of results): To evaluate in a randomized study whether disclosure of actionable genetic results by an eHealth intervention...
Eligibility Criteria
Inclusion
- Potential subjects will include select individuals who participated in Penn Medicine Biobank, Institutional Review Board (IRB) protocol number 813913.
- English speaking
- Age 18 years or older
- Have an actionable genetic mutation (See Appendix A) or have been selected as a control participant
- Agreed to be re-contacted in the future or were not provided the opportunity to indicate a preference
Exclusion
- Deceased assessed by electronic medical record, death index or identified after contact
- Evidence in the clinical record that the subject has already received the same actionable result through clinical genetic testing
Key Trial Info
Start Date :
October 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT06089954
Start Date
October 20 2023
End Date
March 31 2026
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104